13:15 uur 15-03-2022

Inversago Pharma kondigt dosering aan van eerste deelnemer met metabool syndroom in fase 1B klinische studie

MONTREAL–(BUSINESS WIRE)– Inversago Pharma Inc. (“Inversago”), een biotechbedrijf in de klinische fase met een unieke portefeuille van CB1 inverse agonisten, heeft vandaag de dosering aangekondigd van de eerste deelnemer met metabool syndroom in een klinische fase 1b-studie.

Deze 28-daagse proef zal de farmacokinetiek en het veiligheidsprofiel van Inversago’s hoofdmolecuul, INV-202, testen op een doelgroep met metabool syndroom. Topline resultaten van 40 proefpersonen worden in de tweede helft van het kalenderjaar verwacht.

“We zijn verheugd dat de klinische proeven voor INV-202, onze eerste in zijn klasse, perifere CB1-remmer, snel vorderen”, zei Dr. François Ravenelle, Chief Executive Officer van Inversago. “Deze farmacokinetische en veiligheidsstudie zal ook een aantal algemeen aanvaarde biomarkers van stofwisselingsstoornissen meten. Samen zullen deze resultaten naar verwachting als leidraad dienen voor de volgende fase van de ontwikkeling van INV-202.”

Inversago Pharma Announces Dosing of First Participant With Metabolic Syndrome in Phase 1B Clinical Trial

MONTREAL–(BUSINESS WIRE)– Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome in a Phase 1b clinical trial.

This 28-day trial will test the pharmacokinetics and safety profile of Inversago’s lead molecule, INV-202, on a targeted population with metabolic syndrome. Topline results from 40 subjects are expected in the second half of the calendar year.

“We are pleased that the clinical trials for INV-202, our first-in-class, peripheral CB1 inhibitor, are moving ahead swiftly,” said Dr. François Ravenelle, Chief Executive Officer of Inversago. “This pharmacokinetic and safety study will also measure a number of well accepted biomarkers of metabolic disorders. Together, these results are expected to act as a guide for the next phase of INV-202’s development.”

Inversago is planning to launch its first Phase 2 study in patients with Diabetic Nephropathy (DN) shortly after results are available. DN involves a chronic loss of kidney function in people with type-1 and type-2 diabetes who also often present obesity. This patient profile allows for the objective measurement of primary endpoints specific to DN and secondary endpoints relevant to metabolic diseases at large. The company believes that this choice of indication provides the optimal proof of concept to demonstrate the therapeutic breadth of opportunity available to INV-202 and the rest of the Inversago pipeline.

Peripheral CB1 inverse agonists, such as Inversago’s lead INV-202 molecule, have demonstrated efficacy in addressing multiple pathways involved in renal injury. Aside effects on albuminuria in pre-clinical models, CB1 inverse agonists have shown clinical improvements in lipids, weight loss and glucose. Each of these effects have separately demonstrated reno-protective characteristics.

About Inversago Pharma

Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF). For more information, visit inversago.com.

Contacts

François Ravenelle, PhD

Chief Executive Officer

Inversago Pharma Inc.

info@inversago.com

Check out our twitter: @NewsNovumpr